Home LiteratureArticle Details
PMID: 2939794 Published · ppublish English Clinical Trial Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers.

Antimicrobial agents and chemotherapy ·Vol. 28 ·No. 2 ·1985-08-00 ·Pages 235-9

Gonzalez MA, Moranchel AH, Duran S, Pichardo A, Magana JL, Painter B, Forrest A, Drusano GL

Abstract

We administered multiple doses of ciprofloxacin intravenously over 30 min every 12 h for 1 week to nine healthy volunteers. Three volunteers received a placebo (vehicle) intravenously. Doses of 100, 150, and 200 mg were evaluated with a 1-week wash-out period intervening between each dose level. Terminal excretion half-lives averaged 3.67 +/- 0.65, 3.60 +/- 0.26, and 4.00 +/- 0.69 h for the 100-, 150-, and 200-mg doses, respectively. Serum clearances were 30.1 +/- 3.4, 29.8 +/- 4.0, and 26.9 +/- 4.1 liters/h per 1.73 m2 for these doses. Urine concentrations remained in excess of the MIC for 90% of the relevant urinary tract pathogens for the full 12-h dosing interval at each dose. Renal clearance accounted for 56 to 71% of the serum clearance. However, because a microbiologic assay was used and biologically active, renally excreted metabolites were identified, the renal clearance determinations are likely to be in excess of the true values. The doses of ciprofloxacin administered intravenously were well tolerated, and the drug concentrations appeared adequate for the treatment of the vast majority of cases of nosocomially acquired sepsis and urinary tract infections. For patients with serious Pseudomonas infections and perhaps staphylococcal infections, either an 8-h dosing schedule or larger doses on a 12-h schedule should be considered.

MeSH Terms
Adolescent Adult Ciprofloxacin Drug Administration Schedule Drug Tolerance Humans Injections, Intravenous Kinetics Male Metabolic Clearance Rate Middle Aged Quinolines/administration & dosage,metabolism Statistics as Topic
Chemicals
Quinolines Ciprofloxacin
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Gonzalez M A
Moranchel A H
Duran S
Pichardo A
Magana J L
Painter B
Forrest A
Drusano G L
References (7)
7 references, click to expand
  1. Simplified, accurate method for antibiotic assay of clinical specimens.
    Appl Microbiol. 1966 Mar;14(2):170-7 PMID: 4959982
  2. A program package for simulation and parameter estimation in pharmacokinetic systems.
    Comput Programs Biomed. 1979 Mar;9(2):115-34 PMID: 761456
  3. Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.
    Antimicrob Agents Chemother. 1984 Mar;25(3):319-26 PMID: 6232895
  4. Comparison of high-pressure liquid chromatography and bioassay for determination of ciprofloxacin in serum and urine.
    Antimicrob Agents Chemother. 1985 Mar;27(3):353-6 PMID: 3158274
  5. Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid.
    Antimicrob Agents Chemother. 1984 May;25(5):633-7 PMID: 6233935
  6. Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers.
    Antimicrob Agents Chemother. 1984 Nov;26(5):741-4 PMID: 6517556
  7. In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent.
    Antimicrob Agents Chemother. 1984 Mar;25(3):331-5 PMID: 6721464
Article Info
Journal
Antimicrobial agents and chemotherapy
Abbr.
Antimicrob Agents Chemother
ISSN
0066-4804
Published
1985-08-00
Pages
235-9
Language
English
Region
United States
NLM ID
0315061
PMCID
PMC180225
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]